Choriogonadotropin alpha is indicated in the treatment of adult women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): Choriogonadotropin alpha is administered to trigger final follicular maturation and luteinisation after stimulation of follicular growth.
For this indication, competent medicine agencies globally authorize below treatments:
Subcutaneous
250 - 250 ug
From 250 To 250 ug once every day
The maximum dose is 250 micrograms. The following dose regimen should be used in women undergoing superovulation prior to assisted reproductive techniques such as in vitro fertilisation (IVF): One pre-filled syringe of choriogonadotropin alpha (250 micrograms) is administered 24 to 48 hours after the last administration of a follicle stimulating hormone (FSH) or human menopausal gonadotropin (hMG) preparation, i.e. when optimal stimulation of follicular growth is achieved.